These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38767981)

  • 1. Immunotherapy in Alzheimer's disease: focusing on the efficacy of gantenerumab on amyloid-β clearance and cognitive decline.
    Azargoonjahromi A
    J Pharm Pharmacol; 2024 Sep; 76(9):1115-1131. PubMed ID: 38767981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β.
    Bohrmann B; Baumann K; Benz J; Gerber F; Huber W; Knoflach F; Messer J; Oroszlan K; Rauchenberger R; Richter WF; Rothe C; Urban M; Bardroff M; Winter M; Nordstedt C; Loetscher H
    J Alzheimers Dis; 2012; 28(1):49-69. PubMed ID: 21955818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies.
    Fuller JP; Stavenhagen JB; Christensen S; Kartberg F; Glennie MJ; Teeling JL
    Acta Neuropathol; 2015 Nov; 130(5):699-711. PubMed ID: 26433971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact.
    Boess FG; Scelsi MA; Grimmer T; Perry RJ; Tonietto M; Klein G; Hofmann C; Salami M; Wojtowicz J; Lansdall CJ; Lane C; Kerchner GA; Smith J; Doody RS
    J Prev Alzheimers Dis; 2024; 11(3):537-548. PubMed ID: 38706270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice.
    Jacobsen H; Ozmen L; Caruso A; Narquizian R; Hilpert H; Jacobsen B; Terwel D; Tanghe A; Bohrmann B
    J Neurosci; 2014 Aug; 34(35):11621-30. PubMed ID: 25164658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
    Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
    Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
    Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
    Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational Investigation of Gantenerumab and Crenezumab Recognition of Aβ Fibrils in Alzheimer's Disease Brain Tissue.
    Chen Y; Wei G; Zhao J; Nussinov R; Ma B
    ACS Chem Neurosci; 2020 Oct; 11(20):3233-3244. PubMed ID: 32991803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
    Bateman RJ; Smith J; Donohue MC; Delmar P; Abbas R; Salloway S; Wojtowicz J; Blennow K; Bittner T; Black SE; Klein G; Boada M; Grimmer T; Tamaoka A; Perry RJ; Turner RS; Watson D; Woodward M; Thanasopoulou A; Lane C; Baudler M; Fox NC; Cummings JL; Fontoura P; Doody RS;
    N Engl J Med; 2023 Nov; 389(20):1862-1876. PubMed ID: 37966285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
    Silvestro S; Valeri A; Mazzon E
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
    Klein G; Delmar P; Voyle N; Rehal S; Hofmann C; Abi-Saab D; Andjelkovic M; Ristic S; Wang G; Bateman R; Kerchner GA; Baudler M; Fontoura P; Doody R
    Alzheimers Res Ther; 2019 Dec; 11(1):101. PubMed ID: 31831056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.
    Lu D; Dou F; Gao J
    Drug Discov Ther; 2023; 17(6):440-444. PubMed ID: 38220210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.
    Panza F; Solfrizzi V; Imbimbo BP; Giannini M; Santamato A; Seripa D; Logroscino G
    Expert Rev Neurother; 2014 Sep; 14(9):973-86. PubMed ID: 25081412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
    Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
    Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gantenerumab for the treatment of Alzheimer's disease.
    Delrieu J; Ousset PJ; Vellas B
    Expert Opin Biol Ther; 2012 Aug; 12(8):1077-86. PubMed ID: 22583155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile of gantenerumab and its potential in the treatment of Alzheimer's disease.
    Novakovic D; Feligioni M; Scaccianoce S; Caruso A; Piccinin S; Schepisi C; Errico F; Mercuri NB; Nicoletti F; Nisticò R
    Drug Des Devel Ther; 2013; 7():1359-64. PubMed ID: 24255592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.
    Söderberg L; Johannesson M; Nygren P; Laudon H; Eriksson F; Osswald G; Möller C; Lannfelt L
    Neurotherapeutics; 2023 Jan; 20(1):195-206. PubMed ID: 36253511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
    Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
    Elife; 2020 Jun; 9():. PubMed ID: 32510331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
    Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
    ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
    Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
    J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.